ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for AMGEN
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to biosimilars, generally Issues related to drug pricing, value, and transparency, generally Issues related to the importation of prescription medicines Issues relating to the 340B Drug Pricing Program Issues involving the Federal, Food, Drug and Cosmetic Act (FFDCA), generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Medicare/Medicaid MMM
Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Medicare Part B coverage and reimbursement issues Issues related to Medicare Part D Coding and reimbursement for oncology drugs/biologics/biosimilars Issues relating to the 340B Drug Pricing Program Transitional drug add-on payment (TDAPA)i
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.